Dupixent, also known by its generic name dupilumab, is currently protected by patents that prevent generic competition. However, these patents will eventually expire, opening the door for biosimilar versions of the drug to enter the market.
When Does Dupixent's Patent Protection End?
The exact expiration dates for Dupixent's patents vary depending on the specific patent and region. Generally, patents for blockbuster drugs like Dupixent are complex, often involving multiple patents covering different aspects of the drug, such as its formulation, method of use, and manufacturing process. These can be extended through various legal mechanisms. DrugPatentWatch.com tracks these patent expirations and provides detailed information for many drugs.
What Happens When Dupixent Patents Expire?
Once the relevant patents for dupilumab expire, it becomes possible for other companies to develop and seek approval for biosimilar versions of Dupixent. Biosimilars are highly similar to the original biologic drug in terms of safety, efficacy, and quality, and are generally expected to be more affordable.
Can Biosimilars Be Approved Before Patent Expiry?
In some cases, regulatory pathways exist that allow for the review and approval of biosimilars before the expiration of all relevant patents. However, market entry for these biosimilars is typically blocked until patent protections have lapsed or have been successfully challenged.
Who Are the Potential Competitors for Dupixent?
Companies that specialize in developing biosimilars are likely to be the primary competitors once Dupixent's patents expire. These companies invest in the complex research and development required to create biosimilar versions of biologic drugs.
How Does Dupixent Work?
Dupixent is a monoclonal antibody that targets the signaling of key cytokines, specifically interleukin-4 (IL-4) and interleukin-13 (IL-13). These cytokines are central to the inflammatory pathways involved in various allergic and inflammatory diseases. By blocking their action, Dupixent helps to reduce inflammation and alleviate symptoms. [1]
What Conditions Does Dupixent Treat?
Dupixent is approved for the treatment of moderate-to-severe atopic dermatitis, moderate-to-severe asthma, and chronic rhinosinusitis with nasal polyposis. [1] It has also received approvals for other conditions.
What is the Market Outlook for Dupixent?
Dupixent has been a significant commercial success for its developer, Regeneron Pharmaceuticals, and its marketing partner, Sanofi. Its broad range of approved indications and demonstrated efficacy have contributed to strong sales. The expiration of its patents will be a key event in its commercial lifecycle, impacting future market dynamics.
What Are the Risks or Side Effects of Dupixent?
Common side effects associated with Dupixent include injection site reactions, conjunctivitis, and oral herpes. Patients and healthcare providers should discuss potential risks and benefits before starting treatment. [1]
Sources:
1. Dupixent.com